Published in N Engl J Med on July 26, 2012
Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data. BMJ (2014) 1.50
Skin changes following organ transplantation: an interdisciplinary challenge. Dtsch Arztebl Int (2014) 1.39
Dual mTORC1/C2 inhibitors suppress cellular geroconversion (a senescence program). Oncotarget (2015) 1.23
Immunosuppressants in cancer prevention and therapy. Oncoimmunology (2013) 1.17
Rejuvenating immunity: "anti-aging drug today" eight years later. Oncotarget (2015) 1.13
Lifespan extension and cancer prevention in HER-2/neu transgenic mice treated with low intermittent doses of rapamycin. Cancer Biol Ther (2014) 1.08
Cancer in the transplant recipient. Cold Spring Harb Perspect Med (2013) 1.06
Selective anti-cancer agents as anti-aging drugs. Cancer Biol Ther (2013) 1.06
HPV-related cancers after solid organ transplantation in the United States. Am J Transplant (2013) 1.03
Inhibitors of mTOR and risks of allograft failure and mortality in kidney transplantation. Am J Transplant (2012) 0.93
Skin cancer in solid organ transplant recipients: are mTOR inhibitors a game changer? Transplant Res (2015) 0.91
Acute GVHD prophylaxis with standard-dose, micro-dose or no MTX after fludarabine/melphalan conditioning. Bone Marrow Transplant (2013) 0.86
Merkel cell carcinoma in immunosuppressed patients. Cancers (Basel) (2014) 0.86
Squamous cell carcinoma of the skin: Emerging need for novel biomarkers. World J Clin Oncol (2013) 0.85
Peripheral natural killer cell and allo-stimulated T-cell function in kidney transplant recipients associate with cancer risk and immunosuppression-related complications. Kidney Int (2015) 0.85
Skin cancer in organ transplant recipients: more than the immune system. J Am Acad Dermatol (2014) 0.84
Cutaneous Squamous Cell Carcinomas in Organ Transplant Recipients. J Clin Med (2015) 0.83
Rapatar, a nanoformulation of rapamycin, decreases chemically-induced benign prostate hyperplasia in rats. Oncotarget (2015) 0.83
New perspectives on mTOR inhibitors (rapamycin, rapalogs and TORKinibs) in transplantation. Br J Clin Pharmacol (2016) 0.83
Recent progress in genetics of aging, senescence and longevity: focusing on cancer-related genes. Oncotarget (2012) 0.82
Roles of mTOR complexes in the kidney: implications for renal disease and transplantation. Nat Rev Nephrol (2016) 0.82
Post-transplantation malignancies: here today, gone tomorrow? Nat Rev Clin Oncol (2015) 0.81
A randomized, controlled trial of everolimus-based dual immunosuppression versus standard of care in de novo kidney transplant recipients. Transpl Int (2014) 0.80
The fibronectin/α3β1 integrin axis serves as molecular basis for keratinocyte invasion induced by βHPV. Oncogene (2016) 0.80
Incidence, risk factors and outcomes of de novo malignancies post liver transplantation. World J Hepatol (2016) 0.78
Transplantation: Sirolimus for secondary SCC prevention in renal transplantation. Nat Rev Nephrol (2012) 0.78
Circulating TGF-β1 and VEGF and risk of cancer among liver transplant recipients. Cancer Med (2015) 0.78
Revision of immunosuppression in a solid organ transplant recipient leads to complete remission of metastatic undifferentiated carcinoma. JAAD Case Rep (2015) 0.78
PI3K-AKT signaling is a downstream effector of retinoid prevention of murine basal cell carcinogenesis. Cancer Prev Res (Phila) (2014) 0.78
Malignancies after pediatric kidney transplantation: more than PTLD? Pediatr Nephrol (2013) 0.78
Corticosteroid and calcineurin inhibitor sparing regimens in kidney transplantation. Nephrol Dial Transplant (2013) 0.78
Sebaceous carcinoma of the suprapubic area in a liver transplant recipient. Ann Dermatol (2014) 0.77
Premalignant and Malignant Skin Lesions in Two Recipients of Vascularized Composite Tissue Allografts (Face, Hands). Case Rep Transplant (2015) 0.77
Inhibition of Akt Enhances the Chemopreventive Effects of Topical Rapamycin in Mouse Skin. Cancer Prev Res (Phila) (2016) 0.77
Finding the safe place between the hammer and the anvil: sounding the depth of therapeutic immunosuppression. Kidney Int (2015) 0.77
Cyclosporine A immunosuppression drives catastrophic squamous cell carcinoma through IL-22. JCI Insight (2016) 0.76
Are patients with inflammatory eye disease treated with systemic immunosuppressive therapy at increased risk of malignancy? J Ophthalmic Inflamm Infect (2013) 0.75
More than skin deep? Potential nicotinamide treatment applications in chronic kidney transplant recipients. World J Transplant (2016) 0.75
The cutting edge of skin cancer in transplant recipients: scientific retreat of international transplant Skin Cancer Collaborative and Skin Cancer in Organ Transplant Patients Europe. Am J Transplant (2014) 0.75
Sirolimus effects on cancer incidence after kidney transplantation: a meta-analysis. Cancer Med (2015) 0.75
Malignant and noninvasive skin tumours in renal transplant recipients. Dermatol Res Pract (2014) 0.75
Epstein-Barr Virus-Positive Posttransplant Lymphoproliferative Disease After Solid Organ Transplantation: Pathogenesis, Clinical Manifestations, Diagnosis, and Management. Transplant Direct (2015) 0.75
Melanoma in organ transplant recipients: incidence, outcomes and management considerations. J Skin Cancer (2012) 0.75
Clinical and Economic Consequences of Early Cancer after Kidney Transplantation in Contemporary Practice. Transplantation (2016) 0.75
From rapalogs to anti-aging formula. Oncotarget (2017) 0.75
Can the risk of skin cancer after transplantation be reduced by mTOR Inhibitors? Am J Kidney Dis (2013) 0.75
Open-Label, Randomized Study of Transition From Tacrolimus to Sirolimus Immunosuppression in Renal Allograft Recipients. Transplant Direct (2016) 0.75
Safety and Efficacy Endpoints for Mesenchymal Stromal Cell Therapy in Renal Transplant Recipients. J Immunol Res (2015) 0.75
Reviewing 15 years of experience with sirolimus. Transplant Res (2015) 0.75
Sirolimus and skin-cancer prevention in kidney transplantation. N Engl J Med (2012) 0.75
Gerosuppression by pan-mTOR inhibitors. Aging (Albany NY) (2016) 0.75
Phosphoinositide 3-Kinase-Dependent Signalling Pathways in Cutaneous Squamous Cell Carcinomas. Cancers (Basel) (2017) 0.75
Risk of Second Malignancies in Solid Organ Transplant Recipients Who Develop Keratinocyte Cancers. Cancer Res (2017) 0.75
Sirolimus Increases T-Cell Abundance in the Sun Exposed Skin of Kidney Transplant Recipients. Transplant Direct (2017) 0.75
Systematic review of the empirical evidence of study publication bias and outcome reporting bias. PLoS One (2008) 13.32
Skin cancers after organ transplantation. N Engl J Med (2003) 6.65
Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N Engl J Med (2008) 6.60
Belatacept and Long-Term Outcomes in Kidney Transplantation. N Engl J Med (2016) 5.31
Ribavirin for chronic hepatitis E virus infection in transplant recipients. N Engl J Med (2014) 4.70
Retracted Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus. Nat Immunol (2009) 3.84
New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation (2003) 3.79
Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology (2012) 3.48
RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol (2011) 3.43
First human face allograft: early report. Lancet (2006) 3.01
Multifocal epithelial tumors and field cancerization from loss of mesenchymal CSL signaling. Cell (2012) 2.75
Mutations in INF2 are a major cause of autosomal dominant focal segmental glomerulosclerosis. J Am Soc Nephrol (2011) 2.63
High-efficiency postdilution online hemodiafiltration reduces all-cause mortality in hemodialysis patients. J Am Soc Nephrol (2013) 2.62
Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output. JAMA (2012) 2.56
Capillary malformation-arteriovenous malformation, a new clinical and genetic disorder caused by RASA1 mutations. Am J Hum Genet (2003) 2.56
Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol (2013) 2.47
Clinical and epidemiological assessment of steroid-resistant nephrotic syndrome associated with the NPHS2 R229Q variant. Kidney Int (2009) 2.40
Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome. Blood (2009) 2.33
Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation (2009) 2.33
Directed differentiation of human pluripotent cells to ureteric bud kidney progenitor-like cells. Nat Cell Biol (2013) 2.20
Blastic NK-cell lymphomas (agranular CD4+CD56+ hematodermic neoplasms): a review. Am J Clin Pathol (2005) 2.15
Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD). Nephrol Dial Transplant (2005) 2.09
Daclizumab versus antithymocyte globulin in high-immunological-risk renal transplant recipients. J Am Soc Nephrol (2009) 2.08
Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial. Clin Cancer Res (2011) 2.06
Outcomes 18 months after the first human partial face transplantation. N Engl J Med (2007) 2.05
Factors associated with chronic hepatitis in patients with hepatitis E virus infection who have received solid organ transplants. Gastroenterology (2011) 2.01
Hepatitis E virus genotype 3 diversity, France. Emerg Infect Dis (2009) 1.99
Nephrin mutations can cause childhood-onset steroid-resistant nephrotic syndrome. J Am Soc Nephrol (2008) 1.94
Transforming growth factor-beta1 gene polymorphisms are associated with disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2003) 1.93
Treatment of metastatic melanoma with autologous Melan-A/MART-1-specific cytotoxic T lymphocyte clones. J Invest Dermatol (2009) 1.87
Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus. Nephrol Dial Transplant (2005) 1.84
Increases in kidney volume in autosomal dominant polycystic kidney disease can be detected within 6 months. Kidney Int (2008) 1.84
Early low-grade proteinuria: causes, short-term evolution and long-term consequences in renal transplantation. Am J Transplant (2005) 1.82
Patients with autosomal dominant polycystic kidney disease have elevated fibroblast growth factor 23 levels and a renal leak of phosphate. Kidney Int (2010) 1.77
Potential role of soluble ST2 protein in idiopathic nephrotic syndrome recurrence following kidney transplantation. Am J Kidney Dis (2009) 1.77
Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review. Drugs (2007) 1.76
Characteristics of autochthonous hepatitis E virus infection in solid-organ transplant recipients in France. J Infect Dis (2010) 1.75
Progression of coronary artery calcification and thoracic aorta calcification in kidney transplant recipients. Am J Kidney Dis (2011) 1.74
Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol (2006) 1.73
The renal epidemiology and information network (REIN): a new registry for end-stage renal disease in France. Nephrol Dial Transplant (2005) 1.72
Hepatitis E virus and neurologic disorders. Emerg Infect Dis (2011) 1.70
Multivariate analysis of donor risk factors for graft survival in kidney transplantation. Transplantation (2003) 1.69
One-year Results of the Effects of Rituximab on Acute Antibody-Mediated Rejection in Renal Transplantation: RITUX ERAH, a Multicenter Double-blind Randomized Placebo-controlled Trial. Transplantation (2016) 1.68
Influence of a pre-dialysis education programme (PDEP) on the mode of renal replacement therapy. Nephrol Dial Transplant (2005) 1.67
Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial. Transplantation (2011) 1.66
IL-31 expression by inflammatory cells is preferentially elevated in atopic dermatitis. Acta Derm Venereol (2012) 1.66
Dermoscopy of pigmented lesions of the mucosa and the mucocutaneous junction: results of a multicenter study by the International Dermoscopy Society (IDS). Arch Dermatol (2011) 1.63
Zygomycosis in solid organ transplant recipients: a prospective, matched case-control study to assess risks for disease and outcome. J Infect Dis (2009) 1.62
Urine proteomics to detect biomarkers for chronic allograft dysfunction. J Am Soc Nephrol (2008) 1.62
Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial. Transplantation (2016) 1.59
Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial. Ophthalmology (2013) 1.58
HLA mismatches remain risk factors for acute kidney allograft rejection in patients receiving quadruple immunosuppression with anti-interleukin-2 receptor antibodies. Transplantation (2008) 1.58
Opposing roles for calcineurin and ATF3 in squamous skin cancer. Nature (2010) 1.57
Immunosuppressive drugs and the risk of cancer after organ transplantation. N Engl J Med (2005) 1.55
Outcomes of renal transplantation in patients with autosomal dominant polycystic kidney disease: a nationwide longitudinal study. Transpl Int (2011) 1.53
Mycophenolate mofetil monotherapy in membranous nephropathy: a 1-year randomized controlled trial. Am J Kidney Dis (2008) 1.53
INF2 mutations in Charcot-Marie-Tooth disease with glomerulopathy. N Engl J Med (2011) 1.53
An Early Viral Response Predicts the Virological Response to Ribavirin in Hepatitis E Virus Organ Transplant Patients. Transplantation (2015) 1.52
Heterogeneity among patients with tumor necrosis factor receptor-associated periodic syndrome phenotypes. Arthritis Rheum (2003) 1.51
Expectations and strategies regarding islet transplantation: metabolic data from the GRAGIL 2 trial. Transplantation (2007) 1.50
Coronary artery calcification: a strong predictor of cardiovascular events in renal transplant recipients. Nephrol Dial Transplant (2010) 1.50
Pictorial Representation of Illness and Self Measure (PRISM): A novel visual instrument to measure quality of life in dermatological inpatients. Arch Dermatol (2009) 1.50
Post-transplantation lymphoproliferative disorder after kidney transplantation: report of a nationwide French registry and the development of a new prognostic score. J Clin Oncol (2013) 1.50
To biopsy or not to biopsy? Should we screen the histology of stable renal grafts? Transplantation (2007) 1.49
Successful renal retransplantation after post-transplant lymphoproliferative disease. Am J Transplant (2004) 1.48
Decreased prevalence and incidence of HCV markers in haemodialysis units: a multicentric French survey. Nephrol Dial Transplant (2010) 1.48
Anti-human leukocyte antigen immunization after early allograft nephrectomy. Transplantation (2012) 1.47
Donor-specific antibodies after ceasing immunosuppressive therapy, with or without an allograft nephrectomy. Clin J Am Soc Nephrol (2012) 1.46
Renoprotective effects of losartan in renal transplant recipients. Results of a retrospective study. Nephron Clin Pract (2003) 1.46
Lymphoplasmacytic lymphoma causing light chain cast nephropathy. Nephrol Dial Transplant (2012) 1.45
Donor age and ABCB1 1199G>A genetic polymorphism are independent factors affecting long-term renal function after kidney transplantation. J Surg Res (2012) 1.45
Scleromyxedema: a multicenter study of characteristics, comorbidities, course, and therapy in 30 patients. J Am Acad Dermatol (2013) 1.44
Double-dose icodextrin to increase ultrafiltration in PD patients with inadequate ultrafiltration. Perit Dial Int (2011) 1.44
Ribavirin therapy inhibits viral replication on patients with chronic hepatitis e virus infection. Gastroenterology (2010) 1.44
The effects of FK778 in combination with tacrolimus and steroids: a phase II multicenter study in renal transplant patients. Transplantation (2004) 1.44
Influence of immunosuppressive therapy on the natural history of genotype 3 hepatitis-E virus infection after organ transplantation. Transplantation (2010) 1.44
Cytomegalovirus in transplantation - challenging the status quo. Clin Transplant (2007) 1.43
[Medical device evaluation: what are the needs?]. Presse Med (2010) 1.41
Effect of atorvastatin therapy and conversion to tacrolimus on hypercholesterolemia and endothelial dysfunction after renal transplantation. Transplantation (2006) 1.41
Rituximab therapy for acute humoral rejection after kidney transplantation. Transplantation (2007) 1.41
Dual kidney transplantation from uncontrolled deceased donors after cardiac arrest: a possible option. Int J Urol (2013) 1.40
Ecthyma-gangrenosum-like bullous pemphigoid. Dermatology (2010) 1.39
Influence of the ionic dialysance monitor on Kt measurement in hemodialysis. Am J Kidney Dis (2008) 1.39
EGFRvIII expression in squamous cell carcinoma of the skin. JAMA Dermatol (2013) 1.39
The usefulness of P63 detection for differentiating primary from metastatic skin adenocarcinomas. J Cutan Pathol (2008) 1.39
Occult hepatitis C virus infection in hemodialysis patients: examining the evidence. Am J Kidney Dis (2009) 1.39
Prolonged unconsciousness in a patient on automated peritoneal dialysis. Eur J Emerg Med (2006) 1.38
Frequency and clinical implications of development of donor-specific and non-donor-specific HLA antibodies after kidney transplantation. J Am Soc Nephrol (2005) 1.36
Long-term impact of renal transplantation on liver fibrosis during hepatitis C virus infection. Gastroenterology (2002) 1.36
Everolimus retards cyst growth and preserves kidney function in a rodent model for polycystic kidney disease. Kidney Blood Press Res (2007) 1.35
IRF6 is a mediator of Notch pro-differentiation and tumour suppressive function in keratinocytes. EMBO J (2011) 1.33
Villous atrophy induced by mycophenolate mofetil in renal-transplant patients. Transpl Int (2004) 1.31